Mechanistic insights into the immune biomarker of perioperative immune checkpoint inhibitors for non-small cell lung cancer.

Transl Lung Cancer Res · 2025 · PMC12337034 · PMID 40799452

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

NR; HR 0.66) with durvalumab versus placebo, while OS showed a trend toward improvement (NR vs. 53.2 months; HR 0.89) ( 44 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.